Acepodia

Acepodia is developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients.

[Acepodia @AcepodiaInc]

We celebrate Acepodia’s 5-year anniversary with the announcement of FDA clearance of IND application for ACE1831 today! ACE1831 is an antibody armed allogeneic gamma delta2 T-cell Therapy candidate to treat patients with non-Hodgkin’s Lymphoma.

[Acepodia @AcepodiaInc]

Today, we welcomed David Smith to our Board of Directors, as well as Dr. Richard Lopez and Elizabeth Smith to our Scientific Advisory Board! Learn more about our strong roster of industry leaders: https://t.co/JCkiGZhWlk
#biotech #celltherapy

[Acepodia @AcepodiaInc]

We are excited to announce today that we have completed a $109M #SeriesC financing round to help us advance development of our first-in-class #celltherapies! Read more in our press release: https://t.co/rSdfjkLer0

#biotech #celltherapies #drugdevelopment

[Acepodia @AcepodiaInc]

On this special Thanksgiving, we want to share our genuine appreciation for you as this recovery is about a renewed feeling of survival and gratitude. We believe that just a little gratitude can unlock the great fullness of love. May your Thanksgiving be full of peace and joy

[Acepodia @AcepodiaInc]

Thanks for visiting our booth at #MeetTaipei Startup Festival 2021, Vice President @ChingteLai. We appreciate your interest in learning ACC technology and its application in #CellTherapy for cancer patients

[Acepodia @AcepodiaInc]

At today’s @Stifel Healthcare Conference, our Chief Medical Officer Thorsten Graef and Chief Strategy Officer Michael Brock will discuss how we’re advancing next-generation #celltherapies. Tune in from 4:00-4:30 pm ET and learn more here: https://t.co/utdMLXa1JX

#biotech

[Acepodia @AcepodiaInc]

This week, our EVP of R&D Mark Gilbert discusses our proprietary and disruptive ACC platform technology and #oncology pipeline @BioCentury China Healthcare Conference (Nov. 16-19) and @Jefferies Healthcare Conference (Nov. 18-19). Tune in on demand.

#celltherapies #biotech

[Acepodia @AcepodiaInc]

We are honored to be nominated as Top 30 Meet Neo Star for potential outstanding startups this year, hosted by @businessnext.

Our CEO, Dr. Sonny Hsiao will also participate in Neo Star Demo Show on Nov 19. Visit us #MeetTaipei Startup Festival 2021 https://t.co/mIcPzLIvX4

[Acepodia @AcepodiaInc]

Join our CEO, Sonny Hsiao, November 9th at 2:05 PM SGT as he discusses cell and gene therapy trends in Asia at the Lonza APAC Cell and Gene Therapy Event. Register to attend here: https://t.co/AnCmC2iRzf #biotech #celltherapy

[Acepodia @AcepodiaInc]

We’re excited to welcome Robin Andrulevich to our Board of Directors and Eileen Higham to our Scientific Advisory Board as we continue to pioneer first-in-class #celltherapies to address gaps in cancer care! Learn more here: https://t.co/qiTZkg88tO #biotech

[Acepodia @AcepodiaInc]

Thanks to @GeneTherapyLive for sitting down with our Chief Medical Officer Thorsten Graef to discuss the initial clinical data on ACE1702 and how it compares with other NK-based cell therapies. Read the interview here: https://t.co/SvbmhIpA1F

#celltherapy #biotech

[Acepodia @AcepodiaInc]

Our CEO Sonny Hsiao sat down with @GeneTherapyLive to discuss Acepodia’s unique #celltherapy technologies and our clinical programs developing off-the-shelf, allogenic antibody-conjugated #celltherapies. Read the full story here: https://t.co/l2HGbgEtU2

[Acepodia @AcepodiaInc]

Join us tomorrow from 12-12:30 pm ET at the UBS Virtual Biotechnology Private Company Symposium fireside chat, where our executives will share the company’s progress in advancing first-in-class #celltherapies. Register here: https://t.co/3dQhyfh3hE

#biotech

[Acepodia @AcepodiaInc]

Thanks to @endpts for highlighting our preliminary Phase I data for ACE1702 at #ESMO21! Click the link below to learn about the science behind our ACC technology and our initial results.

#celltherapy #cancerresearch #biotech

[Endpoints News @endpts]

Can the antibody-drug conjugate model be applied to an off-the-shelf NK cell therapy? Acepodia uncorked preliminary Phase I data at #ESMO21 that suggest the answer may be yes.

https://t.co/dMIJoBHlFb

[Acepodia @AcepodiaInc]

Today marks an important milestone for Acepodia as we shared positive interim Phase 1 data from our first clinical program with ACE1702 at #ESMO21 with our collaborators @MDAndersonNews. Learn more about the encouraging results here: https://t.co/0jSEw5pGFb

#oncology #biotech

[Acepodia @AcepodiaInc]

We are excited to share initial data at #ESMO21 from our first-in-human Phase 1 study of ACE1702 in patients with advanced HER2+ tumors with our collaborators @MDAndersonNews. Learn more and stay tuned for our e-Poster on 9/16: https://t.co/kKTObQRWSk

#oncology #cancerresearch

[Acepodia @AcepodiaInc]

Join us at this year’s @WellsFargo Virtual Healthcare Conference on September 10 where our executive team will share our progress in advancing first-in-class #celltherapies from 10-10:30 AM ET. View the agenda here: https://t.co/XHQtffcP4W #biotech

[Acepodia @AcepodiaInc]

Our CEO Sonny Hsiao sat down with @GENbio to discuss Acepodia’s unique approach to making next-generation, off-the-shelf #celltherapies based on our antibody-cell conjugation technology. Read more here: https://t.co/oxC0K1tHyJ #bioprocessing

[Acepodia @AcepodiaInc]

If you’re at this year’s BTIG Virtual #Biotechnology Conference, don’t miss our fireside chat today from 12:00-12:25 PM ET where our management team will share our progress on advancing a new class of targeted #celltherapies https://t.co/Pea1S07gMn

[Acepodia @AcepodiaInc]

We’re excited to be part of #BIOAsia_Taiwan2021! Hear from Joe McCracken, our SVP of Business Development, on how Acepodia is developing a new class of targeted #celltherapies called antibody cell effectors for #cancer: https://t.co/TUj7kirdwG #biotech